The Judicial Panel of Multidistrict Litigation assigned the Yasmin And Yaz MDL to Judge David R. Herndon of the Southern District of Illinois. The Yaz/Yasmin/Ocella MDL, docket number 2100 was created for the purposes of consolidating all federal Yaz/Yasmin lawsuits alleging personal injury and wrongful death. The cases are now under the heading IN RE: Yasmin and Yaz (Drospirenone) Marketing and Sales Practices and Products Liability Litigation.

The Judicial Panel found the Southern District of Illinois will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. U.S. District Court Judge David R. Herndon will preside over these Yaz and Yasmin cases for coordinated or consolidated pretrial proceedings. All consolidated actions share factual questions relating to at least one of the drospirenone-containing oral contraceptives Yaz and Yasmin, which are manufactured by Bayer. Plaintiffs in the products liability actions challenge the safety of those oral contraceptives and bring claims for personal injuries or wrongful death stemming from use of the drugs.

Yaz and Yasmin, as well as the generic Ocella, have been associated with various serious side effects, including Blood Clots, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, Cerebrovascular Accidents (CVA), Heart Attack, Myocardial Infarction, Gallbladder Disease / Injury, Gallbladder Removal (cholecystectomy), Kidney Failure or Renal Failure, Pancreatitis and even Death.

Labels: death, DVT, MDL, PE, yasmin, YAZ

Attorneys at Schlichter, Bogard & Denton file Yasmin/Yaz lawsuit

Date Released: 07/24/2009 St. Louis, MO – The attorneys at Schlichter, Bogard & Denton, L.L.P. filed suit this week in Iowa federal court against Bayer alleging that Bayer’s oral contraceptives Yasmin and Yaz are defective and present an increased risk of injury to women. Their client represents her daughter who at the age of 23 died suddenly of multiple bilateral pulmonary embolisms after using Yaz for only 8 months. The client’s daughter was engaged to marry her high school sweetheart. She had also just graduated from college and was to start her first post-graduation position a scant three days after her sudden death. An avid swimmer, plaintiff’s daughter was named to an All American Swim Team three times and gave swim lessons through the American Red Cross. She is survived by her fiancé, parents, two siblings, grandparents, aunts, uncles and cousins.

The lawsuit alleges that Bayer failed to warn the client’s daughter and their physicians of the increased risk of injury, while over-promoting the benefits of the drugs. In October of 2008, the Food and Drug Administration (FDA) sent Bayer a warning letter objecting to its television ads claiming that Yaz has additional benefits compared to other oral contraceptives. The FDA’s letter warned that Yaz actually has additional risks because it contains the progestin drospirenone. The warning prompted an agreement for Bayer to spend $20 million on corrective ads.

Both Yasmin and Yaz have been associated with heart attacks, deep vein thrombosis, pulmonary embolism, stroke and even death in young women.

Schlichter, Bogard & Denton attorneys Roger Denton, Kris Kraft and Beth Wilkins are experienced in litigating dangerous birth control product liability cases. Mr. Denton, Ms. Kraft and Ms. Wilkins are also vigorously litigating suits against the makers of Ortho Evra and NurvaRing in addition to Yasmin/Yaz. Schlichter, Bogard & Denton are lead attorneys on the NuvaRing MDL.

Currently only a handful of Yasmin/Yaz cases across the country have been filed against the manufacturer. Not only are Mr. Denton, Ms. Kraft, and Ms. Wilkins pioneers in these suits across the country, they are also leading their firm’s Yasmin and Yaz litigation and expect to file additional lawsuits in the coming weeks.

Media Contact: Kristine Kraft Schlichter, Bogard & Denton, L.L.P. Phone: 314.621.6115 kkraft@uselaws.com www.uselaws.com

Labels: athlete, Bayer, bilateral pulmonary embolism, death, Deep Vein Thrombosis, DVT, heart attack, Iowa, stroke, YAZ

We have previously posted about some of the dangers of the Yaz birth control pill. Even more information has come out since. Yaz has recently been under heavy scrutiny for possible dangerous side effects such as stroke, pulmonary embolism, and deep vein thrombosis (DVT). Additionally, the FDA and many states’ attorney general have been on Yaz’ case for a different problem: misleading advertising.

The first time Yaz was admonished for misleading the public was through an FDA warning letter in 2003. The letter was in regards to misleading ads that stated that Yaz was “unique” because it contained progestin drospirenone, therefore leading people to believe that Yaz was superior to other birth control pills. Then in 2008, the FDA sent another warning letter concerning two separate television commercials that publicized treatments for which Yaz was not approved. In February of 2009, attorney generals from 27 different states reached a settlement with Yaz to correct misleading information that Yaz put in tv ads that suggested that Yaz was approved for the treatment of PMS and acne. As a result, Yaz is now required to get FDA approval for all ads before they can air on tv.

Yaz was first released in May 2001 and has since become one of the best selling oral contraceptives, with sales over $616 million in 2008. Neither the FDA nor the manufacturer, Bayer, have yet to recall the drug for its serious side effects. Many of the people that take Yaz may have been induced to take it through Yaz’s misleading advertising, and in turn, suffering serious side effects.

For more information, see:
The FDA’s warning letter concerning Yaz:
http://origin.www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm053993.pdf

Wall Street Journal article concerning new ad campaign:
http://www.nytimes.com/2009/02/11/business/11pill.html

Labels: advertising, Air France, birth control, DVT, FDA, NCAA, stroke, Susan Boyle, YAZ

YAZ is the first birth control pill to combine 20 mcg of ethinyl estradiol (EE) with the so-called "fourth generation" progestin drospirenone (DRSP). Fourth generation progestin drospirenone has antimineralocorticoid properties, which means that it can work against the body's normal mechanism for regulating salt and water balance, a situation that can lead to hyperkalemia in high risk patients, resulting in potentially serious heart and health problems. YAZ was approved by the FDA in March 2006.
A company press release, "FDA Approves YAZ(R), The First Oral Contraceptive To Offer Drospirenone In A 24-Day, Active-Pill Regimen", regarding approval of the drug suggests cardiovascular events are not a concern when using YAZ. The press release states:
YAZ contains 3 mg of the progestin drospirenone that has antimineralocorticoid activity, including the potential for hyperkalemia in high-risk patients, comparable to a 25-mg dose of spironolactone. YAZ should not be used in patients with conditions that predispose to hyperkalemia (i.e., renal insufficiency, hepatic dysfunction, or adrenal insufficiency). Women receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium should have their serum potassium levels checked during the first treatment cycle. Medications that may increase serum potassium include ACE inhibitors, angiotensin-ll receptor antagonists, potassium-sparing diuretics, potassium supplementation medications, aldosterone antagonists and NSAIDs.
In YAZ’s current package insert, the warning above is bolded while serious cardiovascular side effects like deep vein thrombosis (DVT), pulmonary embolism (PE), heart attack, and stroke are not emphasized.
The FDA now has some concerns about an association between YAZ and DVT, PE, heart attack, and stroke as demonstrated in the International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC) study.
WebMD even lists blood clots such as pulmonary embolism, stroke or heart attacks as rare but very serious side effects of using YAZ.
There are numerous reports of women suffering from a DVT or a PE while using YAZ pills.
The safety concerns surrounding YAZ are similar to the serious and at times fatal side effects of unsafe birth control like Ortho Evra and NuvaRing.
For more information please see: http://www.fda.gov/medwatch/SAFETY/2007/Jan_PI/Yaz_PI.pdf,
http://origin.www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm053993.pdf
http://www.medicalnewstoday.com/articles/39844.php, http://clinicaltrials.gov/ct2/show/NCT00335257,
http://www.webmd.com/drugs/mono-656-ETHINYL+ESTRADIOL%2FDROSPIRENONE+24%2F4+-+ORAL.aspx?drugid=95358&drugname=YAZ+28+Oral,

Labels: birth control, cardiovascular, death, Deep Vein Thrombosis, DVT, heart attack, PE, pulmonary embolism, stroke, YAZ

Public Citizen, a nonprofit consumer advocacy program, petitioned the FDA asking that it pull Ortho Evra from the market.

Otho Evra, more commonly known as the “birth control patch” or simply “the patch” is about twice as likely to cause blood clots as the birth control pill. That’s because women who use the patch are exposed to a dose of estrogen that is 60% higher than the dose in the pill.

Public Citizen has a long history of success in helping keep dangerous drugs off the market. To name a few victories:

• 1976: a Public Citizen petition lead an FDA ban of chloroform, a cancer-causing chemical, in cough medicine and toothpaste.
• 1982: Oraflex, an arthritis drug, was taken off the market after Public Citizen exposed that it was causing injuries, including death.
• 1985: Upon urging from Public Citizen, the FDA required a label change for aspirin warning of the link between Reye’s Syndrome and the use of aspirin in children.
• 1986: Public Citizen obtained a court order requiring the FDA to add a warning regarding Toxic Shock Syndrome to tampon labels.
• 1996: Public Citizen won a Supreme Court case, confirming the right of injured people to sue medical device manufacturers.
• 2000: Public Citizen lead efforts to ban Rezulin, a deadly diabetes drug.

To read the petition, click here: http://www.citizen.org/pressroom/release.cfm?ID=2654

If you or someone you love has been hurt by Ortho Evra, you may be entitled to compensation. Contact the expert Ortho Evra attorneys at Schlichter, Bogard and Denton for a free consultation.

Labels: birth control patch, blood clot, DVT, Ortho Evra, patch, Public CIitizen

Hundreds of women throughout the country are the victims of serious injuries caused by the NuvaRing. They have suffered strokes and blood clots, and many of them died. 150 or more women or their families have filed lawsuits against Organon, the maker of the NuvaRing, for the injuries and deaths it has caused.

The NuvaRing is a vaginal contraceptive ring that provides monthly birth control by inserting it against the cervix. It uses a type of synthetic hormone that is different from the one used in traditional birth control pills and is more dangerous.

If you or someone you love has been hurt by the NuvaRing, you may be entitled to compensation. Contact the expert attorneys at Schlichter, Bogard & Denton for a free consultation.

nuvaring@uselaws.com
nationalinjuryattorneys@uselaws.com
314-621-6115

For more information, see the following links:

Woman warns others not to use NuvaRing

Schering-Plough, Akzo Nobel sued over NuvaRing contraceptive device

Wrongful Death Lawsuit Filed Over NuvaRing

Labels: attorney, birth control, blood clot, contraception, death, DVT, lawyer, Nuva Ring, NuvaRing, stroke, thrombosis